

Investor Newsletter

Issue 09 2022



MicroPort® Announces Important Follow-up Results at ESC Congress 2022

MicroPort Scientific Corporation (“MicroPort”) recently participated in the European Society of Cardiology (ESC) Congress 2022 in Barcelona, together with its subsidiaries, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort® Coronary”) and Hemovent GmbH (“Hemovent™”). MicroPort® released the 5-year long-term follow-up results of the clinical trial of Firehawk® Coronary Rapamycin-Targeted Eluting Stent System (“Firehawk®”) in a broad all-comers population, referred to as “TARGET AC”. Hemovent™ presented its products in front of the European physicians, attracting a large number of attendees.

Prof. Alexandra Lansky from Yale University School of Medicine, New Haven, US, presented the results of TARGET AC. The 5-year target lesion failure (TLF) was compared between the Firehawk® group and the industry-leading stent group, revealing a rate of 17.1% and 16.3% respectively, and no statistical difference ($p=0.68$). In addition, the reported stent thrombosis rate was 2.8% vs. 3.0% ($p=0.81$), with no statistical difference. The results demonstrate the incidence of very late stent thrombosis of the Firehawk® was low, with 1.3% in the Firehawk® group and 1.9% in the industry-leading stent group ($p=0.20$). Additionally, long-term safety and effectiveness of the Firehawk® as a coronary stent system with the lowest drug dosage was reported.


Moreover, Hemovent™ exhibited MOBYBOX®, the first fully integrated Extracorporeal Life Support (ECLS) system with Extracorporeal Membrane Oxygenation (ECMO). MicroPort® fully presented its diverse products at ESC Congress 2022, and it will further develop innovative products to provide complete solutions for patients worldwide.



Endovastec™ Minos™ Abdominal Aortic Stent-Graft and Delivery System Receives Approval for Marketing in Colombia

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently received registration approval from the Colombian National Institute for Drug and Food Surveillance (INVIMA) for the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ System”). Colombia becomes the third Latin American country to approve the Minos™ System, after Brazil and Argentina. The Minos™ System obtained CE marking in 2019 and has been available in 12 overseas markets including Greece, Poland, Spain, Germany, Italy, Croatia, Hungary, Switzerland, Brazil, the Czech Republic, and the United Kingdom.

Colombia, the third most populous country in Latin America, relies heavily on imports of medical devices. The country’s market size has grown rapidly in recent years, with a high demand for aortic and peripheral vascular intervention products. The approval of the Minos™ System in Colombia, following the Endovastec™ Hercules™ line of products, is expected to build a solid foundation for the Company’s development in the Latin American market and expedite the global presence of its products. In the future, Endovastec™ will continue to introduce more high-quality and innovative medical devices to Colombia to benefit more patients in the country.



MicroPort® MedBot™ Listed among the "50 Smartest Companies" in MIT Technology Review

Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™") has been named by MIT Technology Review as one of the "50 Smartest Companies" for 2021 ("MIT TR50"). Mr Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, was invited to attend the EmTech China Global Emerging Technology Summit and MIT TR50 Award Ceremony. As the first surgical robotics company to be selected for MIT TR50 after the list was introduced to China, MicroPort® MedBot™ is committed to providing smart robotic surgical total solutions to extend and reshape lives, and to leading the smart transformation of healthcare with its superior robotics and innovation capabilities.

According to Mr Yu Liu: "The most important technological innovation progress achieved by our group in 2021 is the continuous breakthrough in cutting-edge research and industrial integration in the fields of robotics, intelligent control, sensing and information, as well as the promotion of several innovative surgical robotic products in registered clinical studies and completing such studies. The advantage of MicroPort® MedBot™ lies in that it has mastered the whole chain of underlying technologies, formed a comprehensive surgical robotics technology innovation platform, and has strong product extension and innovation capabilities. We have become the only innovative company in the world with intelligent solutions for five major surgical robotics specialty products. We will further pioneer innovation, accelerate the R&D and industrialization process, lead the maturation and development of robotic surgery, shape the era of robotic intelligent surgery, and realize our vision to 'let there be no difficult surgeries in the world'".



Investor Newsletter

Issue **09** 2022



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com